Skip to content
IRINOTECAN Hydrochloride Injection Print E-mail
Irinotecan
ZoomSee larger image

Please see full prescribing and safety information including boxed warning for Irinotecan vials.

LATEX-FREE • PRESERVATIVE-FREE • AP RATED
 
 
Brand Name Equivalent: CAMPTOSAR® (CAMPTOSAR is a registered trademark of Yakult Honsha Company, Ltd.) 		 Electronic Catalog
Therapeutic Category: Antineoplastic Agent
  • Consider these SAGENT benefits:
  • • Available in:
  •   - 40 mg per 2 mL single-dose vials
  •   - 100 mg per 5 mL single-dose vials
  • • LATEX-FREE
  • • Preservative-free
  • • Discover PreventIV MeasuresSM packaging features:
  •   - Easy-to-read drug name and dosage strength to aid in identifying the right product
  •   - Bar codes included on the vial and carton for ease of scanning
  •   - Unique label design to help products stand out on the shelf
  •   - Yellow and black cytotoxic warning flag designed to caution healthcare workers who handle the product
  • • Enhanced packaging and labeling designed to promote safety and help reduce medication errors
NDC #25021
 Description Strength Fill Volume Concentration
 Container Size Closure Unit of Sale
 Package Insert Storage Requirements Product Photos 360o View
214-02 Amber Vial 40 mg 2 mL 20 mg per mL 5 mL 20 mm 1 Package Insert Package Insert
 Product Photos 360 Product View
214-05 Amber Vial 100 mg 5 mL 20 mg per mL 5 mL 20 mm
 1 Package Insert Package Insert
 Product Photos 360 Product View
 
Irinotecan Catalog Insert    MSDS Sheet    Bar Codes    Wholesaler Item Numbers
WARNINGS:
Irinotecan Hydrochloride Injection should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available. Irinotecan Hydrochloride Injection can induce both early and late forms of diarrhea that appear to be mediated by different mechanisms. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion of Irinotecan Hydrochloride Injection) may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Early diarrhea and other cholinergic symptoms may be prevented or ameliorated by atropine (see PRECAUTIONS, General). Late diarrhea (generally occurring more than 24 hours after administration of Irinotecan Hydrochloride Injection) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Late diarrhea should be treated promptly with loperamide. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia (see WARNINGS). Administration of Irinotecan Hydrochloride Injection should be interrupted and subsequent doses reduced if severe diarrhea occurs (see DOSAGE AND ADMINISTRATION).
Severe myelosuppression may occur (see WARNINGS).
   Please refer to full prescribing information.
   

 [Back to Products page]
LATEX-FREE = There is no natural rubber latex in the vial container closure or label adhesive in this SAGENT product.
This product information is intended for U.S. residents only.  All trademarks and registered trademarks are the property of their respective owners.